Travere’s stock price climbed by 14% following the announcement that it will seek an FDA label expansion for Filspari.

Under the terms of the agreement, EMCORE stockholders will receive $3.10 per share of EMCORE common stock they own. ACT NOW . The Shareholder Vote is scheduled for February 27, 2025. Click here for ...

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

The U.S. IPO market is gaining momentum, with several issuers set for this week. Notably, defense contractor Karman Space & ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...

MaxCyte ( NASDAQ: MXCT) Wednesday said that it had entered into a strategic platform license with TG Therapeutics, a fully integrated, commercial-stage, biopharmaceutical company focused on the ...

MaxCyte (MXCT) announced they are entering into a strategic platform license with TG Therapeutics (TGTX). Under the terms of the agreement, TG ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherap ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...

Deepgram, the leading voice AI platform for enterprise use cases, today announced the launch of Nova-3, its most advanced speech-to-text (STT) model to date. Nova-3 pushes the boundaries of AI-driven ...